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In 2012, Middle East respiratory syndrome coronavirus 
(MERS-CoV) ﬁ rst emerged in a patient who died of 
severe pneumonia in Saudi Arabia.1 Al though most cases 
conﬁ rmed so far in the Middle East have been sporadic 
with an unknown source of infection, human-to-human 
transmission has been reported in health-care and 
household settings.2–4 However, the source of the virus 
and mode of disease transmission remain unknown 
despite detection of a small fragment of sequence 
identical to the EMC/2012 MERS-CoV in a Taphozous 
perforatus bat captured in Saudi Arabia5 and reports of 
cross-reactive antibodies to MERS-CoV in dromedary 
camels in Oman and the Canary Islands.6
A hospital outbreak of MERS in the eastern province 
of Saudi Arabia was previously described,3 with full 
genome analysis of four isolates of the Al-Hasa 
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shock. There is little opportunity for pretreatment in this 
setting and there is invariably a delay to optimum platelet 
inhibition with even the most eﬀ ective oral agents.14 A 
randomised trial of cangrelor versus placebo on top of 
optimum dual oral antiplatelet therapy, including either 
ticagrelor or prasugrel, would help solidify its role in this 
setting. Second, because patients with high-risk non-
STEMI (GRACE score >140) preferentially beneﬁ t from 
early intervention,15 cangrelor, with its rapid onset and 
oﬀ set, might oﬀ er an advantage in this population. Third, 
in centres where pretreatment is not routine clinical 
practice, cangrelor will probably become a preferred 
option. Fourth, cangrelor is an attractive option in 
patients with high-risk anatomic or clinical features 
undergoing same-sitting or ad hoc elective PCI for stable 
coronary artery disease. There is little opportunity to 
beneﬁ t from preloading in these patients and, somewhat 
surprisingly, neither ticagrelor nor prasugrel has been 
formally studied in this large group of patients.
Finally, will cangrelor oﬀ er value for money? The cost 
diﬀ erential between the intravenous infusion of cangrelor 
and a loading dose of an oral antiplatelet drug (ticagrelor, 
prasugrel, or clopidogrel) is likely to be substantial. More-
over, the degree to which the reduction in ischaemic 
events makes cangrelor an overall cost-eﬀ ective strat-
egy will be a major determinant of how widely it is used. 
Despite these considerations, its favourable pharma-
codynamic proﬁ le and eﬀ ectiveness in reducing peri-
procedural events makes cangrelor a useful and welcome 
agent for interventional cardiologists and their patients.
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outbreak combined with ﬁ ve previously identiﬁ ed 
MERS-CoV genomes. The investigators estimated that 
the time of most recent common ancestor (tMRCA) 
was August, 2011 (95% highest posterior density 
[HPD] November, 2009 to April, 2012), and showed 
that the four viruses formed a monophyletic clade. 
The study provided a better understanding of the 
transmission of MERS-CoV within family clusters2,7 and 
in health-care settings.4 Nevertheless, the four cases 
selected were closely linked epidemiologically within 
this outbreak involving four health-care facilities.3
In The Lancet, Matthew Cotten and colleagues8 
further describe the geographical distribution and 
phylogenetic relation of MERS-CoV infections across 
time in Saudi Arabia. This study represents the largest 
number of MERS-CoV genomes described so far, with 
13 complete and eight partial genomes (30–95% 
genome coverage) from 21 clinical MERS samples 
taken from the Al-Hasa outbreak and four other sites 
in Saudi Arabia (Riyadh, Buraidah, Bisha, and Hafr-Al-
Batin). Each of the sequences was derived directly from 
clinical specimens of patients and thus avoided any 
mutations that would be introduced by tissue culture 
passage. The authors report three distinct MERS-CoV 
genotypes, whereas phylogeographic analyses suggest 
that the MERS-CoV zoonotic reservoir is geographically 
dispersed. Furthermore, genetic diversity in the Al-Hasa 
cluster suggests that the hospital outbreak might have 
been caused by more than one virus introduction. The 
data obtained from clinical MERS samples from the 
Al-Hasa cluster and community outbreaks has recorded 
evolution of the MERS-CoV virus in this epidemic 
within Saudi Arabia, and the sequence variations also 
reveal remarkable multiple-tree clusters. The study has 
provided interesting data supporting circulation of 
MERS-CoV since the middle of 2011, with the estimated 
tMRCA as July, 2011 (95% HPD July, 2007 to June, 2012).8
Although the human exposures that result in 
infection remain unknown, this study has added the 
novel ﬁ nding of three distinct MERS-CoV genotypes 
in Riyadh, with at least two distinct lineages probably 
circulating in Riyadh in October, 2012. Disease 
transmission patterns in the epidemic suggest 
both human-to-human transmission and sporadic 
zoonotic events. The current genome sequence set 
is not adequate to discriminate deﬁ ni tively between 
single or multiple zoonotic introductions, but the 
description of the pair of related genomes from 
Riyadh and Bisha and the description of cases in east 
and west Saudi Arabia in both major lineages of the 
tree suggest many zoonotic events. Overall, this is 
an interesting study that extends earlier ﬁ ndings.2,3 
Although this report provides neither direct evidence 
of animal transmission nor the precise mechanism of 
transmission, the information is useful in tracing the 
source and transmission of MERS-CoV.8
There are some examples of the historical role 
and scientiﬁ c value of molecular methods in tracing 
emerging severe acute respiratory infections. After 
the major outbreaks of SARS-CoV in 2003, researchers 
in many countries had applied molecular genome 
analysis to track the viral evolution and spread of the 
disease.9–11 PCR has provided the scientiﬁ c basis for 
direct examination of clinical samples for evidence of 
infection. Similar to MERS-CoV, sequence variations 
were reported in SARS-CoV obtained from diﬀ erent 
patients in this epidemic.9–11 Cotten and colleagues8 
have eﬀ ectively shown that sequence variations in 
the MERS-CoV genome can be applied as a powerful 
molecular method in tracing the route of transmission, 
when used in conjunction with standard epidemiology. 
Furthermore, using the publicly released full genomic 
sequences of SARS-CoV in 2003, various molecular 
detection methods based on RT-PCR were developed. 
Most of the diagnostic assays were initially focused 
on RNA extracted from nasopharyngeal aspirates, 
urine, and stools, but assays based on the analysis 
of RNA extracted from plasma and serum were later 
developed.12,13 Such blood RNA assays (with one targeted 
at the nucleocapsid region and the other the polymerase 
region of the virus genome) allowed the more standard-
ised quantitative expression of viral loads and became 
useful for early SARS diagnosis, with a detection rate of 
up to 80% during the ﬁ rst week of illness, when serology 
diagnosis of SARS was not sensitive at the early stage.12,13 
These quantitative systems, if available, might be useful 
for the early diagnosis of MERS-CoV and can provide 
viral load information that might facilitate prognostic 
assessments of an infected individual.
With the increasing number of sporadic cases of 
MERS in the Middle East, more research is needed into 
the mode of transmission and exposures responsible 
for the sporadic introductions of MERS-CoV into 
human populations. Development of rapid and reliable 
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Although the beneﬁ ts of continuous antismoking media 
campaigns are clear,1  little is known about the eﬀ ects of 
short-term programmes on attempts to quit smoking by 
the general population. In The Lancet, Timothy McAfee 
and colleagues2 report on a national antismoking 
campaign funded by the US Centers for Disease Control 
and Prevention, called “Tips from Former Smokers” 
(Tips), which was delivered via television, print, digital, 
and other media outlets for 3 months. Development 
of advertisements for the Tips campaign was rigorous 
and considered a diverse set of smokers’ opinions about 
what would help them quit. Hard-hitting, emotional, and 
graphic real-life stories were produced that emphasised 
the eﬀ ects of smoking-related disease on quality of life, 
rather than focusing on risk of death.
The eﬀ ectiveness of this public-health education pro-
gramme was assessed by baseline and follow-up surveys of 
a nationally representative sample of 3051 adult smokers 
and 2220 non-smokers. The preva lence of smokers 
reporting a quit attempt rose over the period of the 
campaign (adjusted odds ratio 1·20, 95% CI 1·02–1·40; 
p=0·02). McAfee and colleagues estimated that, nation-
wide, 1·64 million additional smokers made a quit 
attempt during the 3-month Tips campaign, and 220 000 
(95% CI 159 000–282 000) remained abstinent at follow-
up. Furthermore, 4·7 million additional non-smokers 
recommended a cessation service (telephone helpline or 
quit assistance website) and more than 6 million discussed 
the hazards of smoking with family and friends. These 
study ﬁ ndings could be deemed population-speciﬁ c, but 
they should nonetheless encourage low-income and 
middle-income countries that are facing major tobacco 
epidemics—such as China, India, Bangladesh, Egypt, 
Malaysia, Indonesia, and Russia—to develop appropriate 
and cost-eﬀ ective strategies for tobacco control.3
Tobacco dependence has been deﬁ ned as a chronic 
disease,4 and the process of quitting smoking is 
dynamic; therefore, a prolonged campaign might have 
had a greater eﬀ ect. Globally, many long-term anti-
smoking pro grammes have been delivered.1,5 However, 
Tips was the ﬁ rst federally funded, high-exposure, 
national anti smoking media campaign in the USA, 
and it reached almost 80% of the US population. 
McAfee and colleagues used a conservative approach 
to estimate the possible long-term eﬀ ect of the Tips 
campaign. Their ﬁ ndings suggested that more than 
100 000 smokers were likely to have become sustained 
quitters because of the Tips campaign, possibly adding a 
 Eﬀ ects of a short-term mass-media campaign against smoking
diagnostic assays is also urgently needed so that health 
authorities can take appropriate public health measures 
to interrupt disease transmission and contain the virus.
David S Hui
Department of Medicine and Therapeutics, and Stanley Ho 
Centre for Emerging Infectious Diseases, The Chinese University 
of Hong Kong, Hong Kong Special Administrative Region, China
dschui@cuhk.edu.hk
I declare that I have no conﬂ icts of interest.
1 Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 
Isolation of a novel coronavirus from a man with pneumonia in Saudi 
Arabia. N Engl J Med 2012; 367: 1814–20.
2 Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. 
Family cluster of Middle East respiratory syndrome coronavirus 
infections. N Engl J Med 2013; 368: 2487–94.
3 Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East 
respiratory syndrome coronavirus. N Engl J Med 2013; 369: 407–16.
4 Guery B, Poissy J, el Mansouf L, et al. Clinical features and viral diagnosis of 
two cases of infection with Middle East respiratory syndrome coronavirus: 
a report of nosocomial transmission. Lancet 2013; 381: 2265–72.
5 Memish Z, Mishra N, Olival K, et al. Middle East respiratory syndrome 
coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013; published online 
Aug 23. DOI:10.3201/eid1911.131172.
6 Reusken CB, Haagmans BL, Muller MA, et al. Middle East respiratory 
syndrome coronavirus neutralising serum antibodies in dromedary 
camels: a comparative serological study. Lancet Infect Dis 2013; published 
online Aug 8. http://dx.doi.org/10.1016/S1473-3099(13)70164-6.
7 HPA UK Novel Coronavirus Investigation team. Evidence of 
person-to-person transmission within a family cluster of novel 
coronavirus infections, United Kingdom, February 2013. Euro Surveill 
2013; 18: 20427.
8 Cotten M, Watson SJ, Kellam P, et al. Transmission and evolution of the 
Middle East respiratory syndrome coronavirus in Saudi Arabia: a 
descriptive genomic study. Lancet 2013; published online Sept 20. http://
dx.doi.org/10.1016/S0140-6736(13)61887-5.
9 Chim SS, Tsui SK, Chan KC, et al. Genomic characterisation of the severe 
acute respiratory syndrome coronavirus of Amoy Gardens outbreak in 
Hong Kong. Lancet 2003; 362: 1807–08.
10 Chiu RW, Chim SS, Lo YM. Molecular epidemiology of SARS—from Amoy 
Gardens to Taiwan. N Engl J Med 2003; 349: 1875–76.
11 Guan Y, Peiris JS, Zheng B, et al. Molecular epidemiology of the novel 
coronavirus that causes severe acute respiratory syndrome. Lancet 2004; 
363: 99–104.
12 Ng EK, Ng PC, Hon KL, et al. Serial analysis of the plasma concentration 
of SARS coronavirus RNA in pediatric patients with severe acute 
respiratory syndrome. Clin Chem 2003; 49: 2085–88.
13 Ng EK, Hui DS, Chan KC, et al. Quantitative analysis and prognostic 
implication of SARS coronavirus RNA in the plasma and serum of 
patients with severe acute respiratory syndrome. Clin Chem 2003; 
49: 1976–80.
Published Online
September 9, 2013
http://dx.doi.org/10.1016/
S0140-6736(13)61839-5
See Articles page 2003
